These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

946 related items for PubMed ID: 27431312

  • 1. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Lin HH, Feng WC, Lu LC, Shao YY, Hsu CH, Cheng AL.
    Cancer Lett; 2016 Oct 10; 381(1):58-66. PubMed ID: 27431312
    [Abstract] [Full Text] [Related]

  • 2. Bruceine D inhibits hepatocellular carcinoma growth by targeting β-catenin/jagged1 pathways.
    Cheng Z, Yuan X, Qu Y, Li X, Wu G, Li C, Zu X, Yang N, Ke X, Zhou J, Xie N, Xu X, Liu S, Shen Y, Li H, Zhang W.
    Cancer Lett; 2017 Sep 10; 403():195-205. PubMed ID: 28645563
    [Abstract] [Full Text] [Related]

  • 3. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
    Huang M, Chen C, Geng J, Han D, Wang T, Xie T, Wang L, Wang Y, Wang C, Lei Z, Chu X.
    Cancer Lett; 2017 Jul 10; 398():12-21. PubMed ID: 28377178
    [Abstract] [Full Text] [Related]

  • 4. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
    Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward SC, Bruix J, Mazzaferro V, Schwartz M, Friedman SL, Llovet JM.
    Clin Cancer Res; 2012 Sep 15; 18(18):4997-5007. PubMed ID: 22811581
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
    Ma L, Wang X, Jia T, Wei W, Chua MS, So S.
    Oncotarget; 2015 Sep 22; 6(28):25390-401. PubMed ID: 26246473
    [Abstract] [Full Text] [Related]

  • 7. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Chen B, Wei W, Ma L, Yang B, Gill RM, Chua MS, Butte AJ, So S.
    Gastroenterology; 2017 Jun 22; 152(8):2022-2036. PubMed ID: 28284560
    [Abstract] [Full Text] [Related]

  • 8. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L, Li G, Zhu H, Dong X, Zhao D, Jiang X, Li J, Qiao H, Ni S, Sun X.
    Cancer Lett; 2014 Dec 01; 355(1):96-105. PubMed ID: 25218350
    [Abstract] [Full Text] [Related]

  • 13. LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation.
    Fu QH, Zhang Q, Zhang JY, Sun X, Lou Y, Li GG, Chen ZL, Bai XL, Liang TB.
    Tumour Biol; 2016 Jun 01; 37(6):7277-86. PubMed ID: 26666823
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib.
    Mao K, Zhang J, He C, Xu K, Liu J, Sun J, Wu G, Tan C, Zeng Y, Wang J, Xiao Z.
    Cancer Lett; 2014 Oct 01; 352(2):245-52. PubMed ID: 25034398
    [Abstract] [Full Text] [Related]

  • 18. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
    Jia H, Yang Q, Wang T, Cao Y, Jiang QY, Ma HD, Sun HW, Hou MX, Yang YP, Feng F.
    Biochim Biophys Acta; 2016 Jul 01; 1860(7):1417-30. PubMed ID: 27091611
    [Abstract] [Full Text] [Related]

  • 19. Anti-tumor Activity of the Small Molecule Inhibitor PRI-724 Against β-Catenin-activated Hepatocellular Carcinoma.
    Gabata R, Harada K, Mizutani Y, Ouchi H, Yoshimura K, Sato Y, Kitao A, Kimura K, Kouji H, Miyashita T, Tajima H, Ohta T.
    Anticancer Res; 2020 Sep 01; 40(9):5211-5219. PubMed ID: 32878809
    [Abstract] [Full Text] [Related]

  • 20. 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.
    Lu YY, Wang JJ, Zhang XK, Li WB, Guo XL.
    J Pharm Pharmacol; 2015 Oct 01; 67(10):1393-405. PubMed ID: 26076716
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.